Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: nephros.com
Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no
SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl
New Filter Targets Additional Industries and Water Quality Compliance SOUTH ORANGE, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH) Nephros, Inc., a leader in advanced filtration technology, is excited to announce the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader ran
SOUTH ORANGE, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH) Nephros, Inc., a leader in advanced filtration technology, is proud to announce its rapid response to the recent hurricanes which devastated parts of the southeastern United States. Leveraging its significant disaster and emergency response capabilities, Nephros provided crucial water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe supply of water to patients and staff amid recovery efforts. Following natural disasters, access to clean, safe water is paramount for healthcare facilities, where contaminated water may severely compromise patient ca
Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance
SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ
Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co
SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor R
Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2023. Financial Highlights* Third-quarter net revenue of $3.7 million, an increase of 55%;Third-quarter net loss from continuing operations of $0.2 million, compared to $1.3 million;Third-quarter
SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv
B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50
Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no
SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl
Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance
SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ
Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co
SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor R
Third-Quarter Net Revenue of $3.7 Million, a 55% Increase Over 2022; Net Loss from Continuing Operations Narrows 85% to $0.2 Million; $1.1 Million in Positive Year-to-Date Net Cash Flows from Operating Activities SOUTH ORANGE, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2023. Financial Highlights* Third-quarter net revenue of $3.7 million, an increase of 55%;Third-quarter net loss from continuing operations of $0.2 million, compared to $1.3 million;Third-quarter
SOUTH ORANGE, NJ, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Wednesday, November 8, 2023 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be added into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022;Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results SOUTH ORANGE, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2023. Financial Highlights* Net revenue from continuing operations of $3.5 million, an increase of 24%Net loss from continuing operations of $0.4 million, compared to $0.7 millionAdjusted EBITDA from continuing operations of ($0.2 million), compared to ($0.4 million) *Stat
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its second-quarter financial results on Wednesday, August 9, 2023 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be added into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv
SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
SOUTH ORANGE, NJ, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc.(NASDAQ:NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced the appointment of Wes Lobo to the role of Chief Commercial Officer. Mr. Lobo first joined Nephros in February 2021 as Chief Marketing Officer. In the expanded role of Chief Commercial Officer, he will be responsible for all commercial strategy and operations including sales, marketing, business development, product management, and customer service. "As a growth-focused business, Nephros requires a unified commercial organization bui
SOUTH ORANGE, NJ, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Wes Lobo as Chief Marketing Officer, reporting directly to Nephros Chief Executive Officer, Andy Astor. In this role, Wes will be responsible for driving the company’s strategic growth through innovative solutions, go-to-market strategies, and marketing. “Wes brings more than 20 years of expertise in the water business, with broad and deep experience across marketing, strategy, product management, sales, engineering, and leaders
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G/A - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
10-Q - NEPHROS INC (0001196298) (Filer)
8-K - NEPHROS INC (0001196298) (Filer)
8-K - NEPHROS INC (0001196298) (Filer)
10-Q - NEPHROS INC (0001196298) (Filer)
S-8 - NEPHROS INC (0001196298) (Filer)
8-K - NEPHROS INC (0001196298) (Filer)
EFFECT - NEPHROS INC (0001196298) (Filer)
S-3 - NEPHROS INC (0001196298) (Filer)
10-Q - NEPHROS INC (0001196298) (Filer)
8-K - NEPHROS INC (0001196298) (Filer)
The Dow Jones index closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Nephros The Trade: Nephros, Inc. (NASDAQ:NEPH) Director Arthur H Amron bought a total of 5,000 shares at an average price of $2.24. To acquire these shares, it cost around $11,176. What's Happening: On May 9, Nephros posted a narrower-than-expe
Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.
-SEC Filing
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $3.522 million which missed the analyst consensus estimate of $3.734 million by 5.68 percent. This is a 4.73 percent decrease over sales of $3.697 million the same period last year.
Benchmark analyst Robert Wasserman upgrades Nephros (NASDAQ:NEPH) from Hold to Speculative Buy and announces $5 price target.
Nephros (NASDAQ:NEPH) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:15 PM. Here's what investors need to know about the announcement. Earnings Nephros missed estimated earnings by -200.0%, reporting an EPS of $-0.06 versus an estimate of $-0.02. Revenue was up $742 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.04 which was followed by a 3.0% drop in the share price the next day. Here's a look at Nephros's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.06 -0.05 -0.02 -0.06 EPS Actual -0.02 -0.04 -0.03 -0.07 Revenue Estimate 3.35M 3.11M 3.68M 2.80M Revenue Actual 3.74M 3.
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.060) per share which missed the analyst consensus estimate of $(0.030) by 100 percent. The company reported quarterly sales of $3.300 million which missed the analyst consensus estimate of $3.813 million by 13.47 percent. This is a 29.01 percent increase over sales of $2.558 million the same period last year.
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarterly earnings at $0.21 per share on revenue of $354.31 million. • ABM Indus (NYSE:ABM) is projected to report quarterly earnings at $0.71 per share on revenue of $2.01 billion. • Bilibili (NASDAQ:BILI) is likely to report quarterly loss at $0.22 per share on revenue of $887.26 million. • BJ's Wholesale Club (NYSE:BJ) is projected to report quarterly earnings at $1.06 per share on revenue of $5.39 billion. • Burlington Stores (NYSE:BURL) is estimated to report quarterly earnings at $3.30 per
Nephros (NASDAQ:NEPH) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement. Analysts estimate that Nephros will report an earnings per share (EPS) of $-0.02. Nephros bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.04, which was followed by a 2.59% drop in the share price the n
Gainers Interactive Strength (NASDAQ:TRNR) stock moved upwards by 41.0% to $0.9 during Monday's regular session. The market value of their outstanding shares is at $12.9 million. Sleep Number (NASDAQ:SNBR) shares moved upwards by 18.7% to $17.45. The market value of their outstanding shares is at $388.0 million. As per the news, the Q4 earnings report came out 2 days ago. Li Auto (NASDAQ:LI) shares increased by 15.77% to $40.29. The company's market cap stands at $40.3 billion. As per the press release, Q4 earnings came out today. Workhorse Gr (NASDAQ:WKHS) stock moved upwards by 15.08% to $0.33. The company's market cap stands at $86.0 million. Envirotech Vehicles (NASDAQ:EVTV) shares